Having our own in-house Research and Development facility is something that allows us not only to have complete control of the process from start to finish, but also to react quickly to changing conditions and opportunities.

From the introduction of our very first product Synoquin®, the UK’s leading chondroprotective, to the most recent addition, Sustain®, we have continually strived to develop products that can in many cases improve, but primarily complement existing therapies.

Significant investment in this area has and will continue to be at the forefront of the VetPlus business model, as we strive to find better solutions to the problems facing pet owners worldwide.